Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare disease characterized by malignant proliferation of a contingent blastic plasmacytoid dendritic cell. This rare entity is recognized mostly by cutaneous spreading, or not having a leukaemic component. The prognosis is very poor.

[1]  John Wang,et al.  Congenital blastic plasmacytoid dendritic cell neoplasm , 2012, Pediatric blood & cancer.

[2]  F. Jardin,et al.  Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. , 2011, Blood.

[3]  M. Paulli,et al.  Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: focus on biallelic locus 9p21.3 deletion. , 2011, Blood.

[4]  K. Flaherty,et al.  Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  B. Reizis,et al.  Plasmacytoid dendritic cells: recent progress and open questions. , 2011, Annual review of immunology.

[6]  E. Jaffe,et al.  Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications , 2010, Haematologica.

[7]  J. Dering,et al.  Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. , 2010, Neoplasia.

[8]  T. Petrella,et al.  Tumoral aspects of plasmacytoid dendritic cells: What do we know in 2009? , 2010, Autoimmunity.

[9]  M. Angelopoulou,et al.  Acute lymphoplasmacytoid dendritic cell (DC2) leukemia: results from the Hellenic Dendritic Cell Leukemia Study Group. , 2010, Leukemia research.

[10]  T. Petrella,et al.  Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice? , 2010, The British journal of dermatology.

[11]  L. Cerroni,et al.  Cutaneous Manifestations of Blastic Plasmacytoid Dendritic Cell Neoplasm—Morphologic and Phenotypic Variability in a Series of 33 Patients , 2010, The American journal of surgical pathology.

[12]  E. Jaffe,et al.  Plasmacytoid Dendritic Cells: Physiologic Roles and Pathologic States , 2009 .

[13]  L. Thomas,et al.  Haematodermic CD4+CD56+ neoplasm: complete remission after methotrexate–asparaginase treatment , 2009, Clinical and experimental dermatology.

[14]  S. Pileri,et al.  Novel markers of normal and neoplastic human plasmacytoid dendritic cells. , 2008, Blood.

[15]  P. Mclaughlin,et al.  CD4+ CD56+ hematodermic/plasmacytoid dendritic cell tumor with response to pralatrexate. , 2008, Journal of the American Academy of Dermatology.

[16]  F. Garnache-Ottou,et al.  Plasmacytoid dendritic cell leukaemia/lymphoma: towards a well defined entity? , 2007, British journal of haematology.

[17]  M. Herling,et al.  Expression of the plasmacytoid dendritic cell marker BDCA-2 supports a spectrum of maturation among CD4+ CD56+ hematodermic neoplasms , 2006, Modern Pathology.

[18]  A. Bernasconi,et al.  Acute leukemia of dendritic cell lineage in childhood: incidence, biological characteristics and outcome , 2006, Leukemia & lymphoma.

[19]  Nicola Pimpinelli,et al.  WHO-EORTC classification for cutaneous lymphomas. , 2005, Blood.

[20]  M. Teitell,et al.  Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. , 2005, American journal of clinical pathology.

[21]  T. Petrella,et al.  [Agranular CD4+ CD56+ CD123+ hematodermic neoplasm (blastic NK-cell lymphoma) revealed by cutaneous localization: 2 cases]. , 2004, Annales de dermatologie et de vénéréologie.

[22]  T. Petrella,et al.  Localisations cutanées révélatrices d'une hématodermie CD4+ CD56+ CD123+ : 2 cas , 2004 .

[23]  M. Teitell,et al.  TCL1 and CLA expression in agranular CD4/CD56 hematodermic neoplasms (blastic NK-cell lymphomas) and leukemia cutis. , 2004, American journal of clinical pathology.

[24]  T. Rüdiger,et al.  What is CD4+CD56+ malignancy and how should it be treated? , 2003, Bone Marrow Transplantation.

[25]  T. Petrella,et al.  `Agranular CD4+ CD56+ Hematodermic Neoplasm' (Blastic NK-Cell Lymphoma) Originates From a Population of CD56+ Precursor Cells Related to Plasmacytoid Monocytes , 2002, The American journal of surgical pathology.

[26]  B. Drénou,et al.  Clinical and biologic features of CD4(+)CD56(+) malignancies. , 2002, Blood.

[27]  R. Gressin,et al.  Identification of a leukemic counterpart of the plasmacytoid dendritic cells. , 2001, Blood.

[28]  J. Bennett,et al.  Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation, lacking cutaneous involvement: Case series and literature review. , 2012, Leukemia research.

[29]  橋川 恵子.  Clinicopathological features and prognostic significance of CXCL12 in blastic plasmacytoid dendritic cell neoplasm , 2011 .

[30]  C. Meijer,et al.  CD56 1 hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature , 2004 .

[31]  M. Béné,et al.  CD4+ CD56+ lineage negative malignancies: a new entity developed from malignant early plasmacytoid dendritic cells. , 2003, Haematologica.